D. Miller

In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors.

G. M. Briggs, A. Treasurywala, C. Weigelt, 1996, Biochemical pharmacology.

Inhibition of T lymphocyte activation by a novel p56lck tyrosine kinase inhibitor.

C. Faltynek, P. Mauvais, J. Reid, 1995, Journal of enzyme inhibition.

Administration of human recombinant IL-7 to normal and irradiated mice increases the numbers of lymphocytes and some immature cells of the myeloid lineage.

K. Kross, C. Faltynek, D. Miller, 1992, Journal of immunology.

Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity.

D. Murphy, R. Lehr, C. Faltynek, 1995, Biochemistry.

5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.

R. Dolle, M. Bobko, D. Sawutz, 1994, Journal of medicinal chemistry.

WIN 17317-3: novel nonpeptide antagonist of voltage-activated K+ channels in human T lymphocytes.

R. J. Hill, C. Faltynek, D. Miller, 1995, Molecular pharmacology.

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.

J. Gerven, R. Schoemaker, Z. Diamant, 2008, Pulmonary pharmacology & therapeutics.